Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097812 · ClinicalTrials.gov registry record · Phase 3
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT00097812 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 220 participants.
The verdict
NCT00097812, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.
Interventions
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097812
The ClinicalTrials.gov registry entry for NCT00097812 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zoledronic acid is the first listed.
NCT00097812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097812 about?
NCT00097812 is a clinical study titled "Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid". The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.
What is the current status of trial NCT00097812?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2004-05. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00097812?
The interventions under investigation include: zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00097812?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.